Currently, out of the existing stock ratings of Bradley Canino - 51 which are a Buy (77.27%), 15 which are a Hold (22.73%)

Bradley Canino

Work Performance Price Targets & Ratings Chart

Analyst Bradley Canino works at STIFEL and is covering the Healthcare sector with 124 price targets and ratings displayed on 15 stocks. Previously, Bradley Canino worked at CREDIT SUISSE.

Bradley Canino's average stock forecast success ratio is 23.88% with an average time for price targets to be met of 27.4 days.

Most recent stock forecast was given on ALXO, ALX Oncology Holdings at 14-Nov-2023.

Wall Street Analyst Bradley Canino

Analyst best performing recommendations are on AFMD (AFFIMED N.V).
The best stock recommendation documented was for AFMD (AFFIMED N.V) at 10/10/2022. The price target of $2 was fulfilled within 28 days with a profit of $0.41 (25.79%) receiving and performance score of 9.21.

Average potential price target upside

ALXO ALX Oncology Holdings ARVN Arvinas BPMC Blueprint Medicines CCCC C4 Therapeutics DCPH Deciphera Pharmaceuticals TPTX Turning Point Therapeutics ZNTL Zentalis Pharmaceuticals BDTX Black Diamond Therapeutics KYMR Kymera Therapeutics AFMD Affimed N.V MRUS Merus N.V RLAY Relay Therapeutics KURA Kura Oncology SNDX Syndax Pharmaceuticals THRX

Analyst name


Current price target

Potential distance

Previous price target


Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score



$2.16 (27.55%)

20 days ago

0/4 (0%)

$17.79 (52.04%)



$0.16 (2.04%)


1 months 23 days ago

3/3 (100%)

$2.45 (18.21%)




$11.2 (233.33%)


3 months 23 days ago

0/3 (0%)

$18 (199.99%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Bradley Canino is most bullish on?

Potential upside of $24.66 has been obtained for ZNTL (ZENTALIS PHARMACEUTICALS)

Which stock is Bradley Canino is most reserved on?

Potential downside of -$0 has been obtained for KYMR (KYMERA THERAPEUTICS)

What Year was the first public recommendation made by Bradley Canino?

On 2021

To continue looking at which analysts cover the stock please register to the basic or advanced membership

How to use the chart